News
FOLD
6.24
+2.46%
0.15
Weekly Report: what happened at FOLD last week (0707-0711)?
Weekly Report · 17h ago
Weekly Report: what happened at FOLD last week (0630-0704)?
Weekly Report · 07/07 09:59
Amicus Therapeutics Advances Pediatric Fabry Disease Study with Migalastat
TipRanks · 07/03 16:33
Amicus Therapeutics Advances Pompe Disease Research with New Observational Study
TipRanks · 07/03 16:20
Amicus Therapeutics’ Migalastat Study: A Potential Game-Changer for Fabry Disease Treatment
TipRanks · 07/03 16:11
Amicus Therapeutics Expands Access to Migalastat for Fabry Disease Patients
TipRanks · 07/03 16:01
Weekly Report: what happened at FOLD last week (0623-0627)?
Weekly Report · 06/30 10:02
Amicus Therapeutics Completes Key Study on Pompe Disease Treatment Interactions
TipRanks · 06/26 16:08
Amicus Therapeutics' Pombiliti+Opfolda Receives Japan MHLW's Approval For Pompe Treatment
NASDAQ · 06/25 11:47
Amicus announces approval of Pombiliti + Opfolda in Japan
TipRanks · 06/25 11:10
AMICUS THERAPEUTICS ANNOUNCES APPROVAL OF POMBILITI® (CIPAGLUCOSIDASE ALFA) + OPFOLDA® (MIGLUSTAT) IN JAPAN
Reuters · 06/25 11:00
Sangamo rises after trial data for Fabry disease therapy
Seeking Alpha · 06/24 12:46
Weekly Report: what happened at FOLD last week (0616-0620)?
Weekly Report · 06/23 09:59
Weekly Report: what happened at FOLD last week (0609-0613)?
Weekly Report · 06/16 10:02
Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma
Seeking Alpha · 06/12 14:14
Analysts’ Top Healthcare Picks: Amicus (FOLD), Inspire Medical Systems (INSP)
TipRanks · 06/09 13:30
Weekly Report: what happened at FOLD last week (0602-0606)?
Weekly Report · 06/09 10:02
Amicus Stockholders Approve Directors and Equity Plan
TipRanks · 06/05 20:45
New Strong Sell Stocks for June 3rd
NASDAQ · 06/03 11:45
Amicus Therapeutics Announced The Publication Of A Post-hoc Analysis Of Data From The Ert-experienced Cohort Of The PROPEL Study Of Cipaglucosidase Alfa-Atga + Miglustat (Cipa+Mig) In Adults With Late-onset Pompe Disease In Muscle And Nerve
Benzinga · 06/03 11:13
More
Webull provides a variety of real-time FOLD stock news. You can receive the latest news about Amicus Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.